Facebook Instagram Youtube
Speak to our experts

Stem Cell Therapy for Critical Limb-Threatening Ischemia (CLTI)

At the Stem Cells Transplant Institute, we offer stem cell therapy for critical limb ischemia (CLTI) and peripheral artery disease (PAD) to support circulation, improve vascular health, and enhance tissue viability. While not a cure, it may help reduce inflammation and support healing.

Request a consultation
Learn our protocol
Reviewed: 19 Apr 2026

What is Critical Limb-Threatening Ischemia (CLTI)?

Critical Limb-Threatening Ischemia is an advanced stage of peripheral artery disease (PAD) characterized by severely reduced blood flow to the lower extremities. It develops develops when arteries in the legs become severely narrowed or blocked, leading to rest pain, ulcers, non-healing wounds, and risk of tissue loss and amputation. 

Peripheral artery disease affects approximately 200 million people worldwide. Only a smaller subset of patients progress to CLTI; reported estimates vary by population and diagnostic criteria.

CLTI requires comprehensive medical management, wound care, and sometimes revascularization strategies. MSC-based therapy may be considered as an adjunctive approach alongside standard care in some patients, with the goal of supporting microvascular health and the local tissue environment.

request a free consultation

Why Seek Stem Cell Therapy for Critical Limb-Threatening Ischemia (CLTI) in Costa Rica?

Critical Limb-Threatening Ischemia represents one of the more urgent clinical situations our team works with. At Stem Cells Transplant Institute in San José, Costa Rica, MSC vascular protocols are offered within a certified facility for patients who have exhausted standard revascularization options or who have been determined not to be surgical candidates.

Patients from the United States, Canada, and Europe travel to San José to access physician-supervised regenerative programs, particularly in cases where conventional treatment pathways are limited and limb preservation is a primary concern. Costa Rica is accessible, its clinical environment is equipped for complex vascular cases, and the cost difference compared to equivalent private programs in North America is significant.

Before scheduling therapy, all patients undergo a comprehensive vascular assessment to determine candidacy. This pre-treatment review typically includes: evaluation of vascular imaging studies (e.g., angiography, Doppler ultrasound), assessment of ankle-brachial index (ABI) and perfusion status, review of wound condition, tissue viability, and infection, evaluation of comorbidities, including diabetes and cardiovascular disease, and a review of prior revascularization procedures and current medical management.

Common Characteristics

  • Ischemic rest pain in the foot or toes (often worse at night)
  • Non-healing sores, ulcers, or wounds on the feet or legs
  • Skin changes in the lower leg/foot (coolness, dryness, color changes, or shiny appearance)
  • Reduced or absent pulse in the feet
  • Tissue loss, including blackened tissue or gangrene
Evidence-Based Treatment

Why Stem Cell Therapy for CLTI?

Stem cell transplantation uses healthy cells to help support the repair processes of damaged tissues and to promote a more favorable environment for tissue recovery. Transplanted stem cells may also support tissue repair by releasing factors that help create an environment more suitable for cell survival. 

Research suggests that MSCs may help the body: Promote new blood vessel formation (angiogenesis), improve microcirculation in oxygen-deprived tissues, reduce damaging inflammation, support wound healing, improve tissue oxygenation, and support cell survival under ischemic conditions.

Stem cell therapy is a supportive option, not a substitute for vascular intervention or standard PAD/CLTI care. 

Evidence remains preliminary, and ongoing clinical trials are required to confirm these effects.

1

Supporting new blood vessel growth

MSCs may release growth factors — such as VEGF (vascular endothelial growth factor) — that can help support the formation of new small blood vessels, which may contribute to improve tissue oxygenation (Lu et al., 2020).

2

Improving microcirculation

Studies suggest MSCs release natural signals that may help support the repair of small blood vessels and improve circulation in areas where blood flow is reduced. (Dash et al., 2018).

3

Reducing inflammation

Chronic inflammation can worsen CLTI damage. MSCs may release anti-inflammatory and immunomodulatory factors that can help reduce damaging inflammatory signaling (Chen et al., 2018).

Gráfico de barras e icono de línea ascendente en color morado, representando análisis de datos, crecimiento financiero y estadísticas de rendimiento.
4

Supporting wound healing and tissue recovery

MSC-secreted factors may support collagen organization and tissue repair processes, contributing to improved wound healing in ischemic skin and soft tissue (Bura et al., 2014).

Icono minimalista de un cerebro humano de color púrpura que destaca la división entre los dos hemisferios cerebrales sobre un fondo negro sólido.
request a free consultation

Expected Benefits & Clinical Observations

Although individual responses vary widely, published studies and clinical observations have reported potential supportive improvement in the following functional domains:

Microcirculation improvement
25-40%
Rest pain reduction
40-60%
Icono morado de luna creciente y dos estrellas sobre fondo lila, simbolizando el modo nocturno, descanso o configuración de tema oscuro en una interfaz de usuario.
Improved wound healing
50-70%
Lower major amputation risk
20-30%

*These percentages summarizes ranges reported in selected clinical studies and observational cohorts under controlled conditions and standardized outcomes measures. They are not specific to any single study or to treatments performed at Stem Cells Transplant Institute. They should not be interpreted as averages, promises, or guaranteed results for individual patients. Evidence for MSC therapy in Critical Limb-Threatening Ischemia remains preliminary, and ongoing controlled clinical trials are still evaluating the magnitude, durability and consistency of these effects. All observations should be considered exploratory and hypothesis-generating rather than definitive proof of efficacy.

Timeline of Reported Improvements

Published studies and patient-reported outcomes suggest that improvements after mesenchymal stem cell (MSC) therapy for CLTI may develop gradually over time. These timelines are illustrative summaries rather than predictions, and individual responses vary significantly.

1-3 months
Some patients may experience less pain or improved wound comfort.
3-6 months
Improvements in circulation may become more noticeable in some patients
6-12 months
Tissue-repair patterns and microvascular changes have been reported in some studies and patient observations

*These timelines summarize patterns reported across selected published studies and observational cohorts. They are not specific predictions, and they do not represent expected outcomes for any individual patient. Individual experiences vary considerably, and some patients may experience minimal or no improvement. Evidence for MSC therapy in CLTI remains preliminary, and larger controlled clinical trials are needed to validate these observations. All timelines should be interpreted as exploratory and non-confirmatory.

request a free consultation

Patient Stories & Testimonials

Frequently Asked Questions

Stem cell therapy cannot ensure that amputation can be avoided. Results vary from person to person and depend on many factors, including how advanced the disease is, existing blood flow, wound condition, and whether procedures to restore circulation are possible. Some studies have observed improvements in blood flow–related measures and wound healing, but responses differ widely among individuals.

We use mesenchymal stem cells (MSCs) — often umbilical-cord–derived or autologous bone marrow MSCs — because they are widely studied for immunomodulatory and tissue-supportive effects. For CLTI, we may combine the cell protocol with supportive adjunct such as antioxidant infusions (e.g., vitamin C and glutathione), ozone therapy, and platelet-rich plasma (PRP), depending on the patient’s clinical profile. These adjunct therapies are intended to support overall tissue and recovery conditions; they do not guarantee improved outcomes.

Yes. Stem cell therapy does not replace standard treatments such as vascular procedures to restore blood flow, prescribed medications (including blood-thinning or cholesterol-lowering therapies), or proper wound care. When appropriate, it may be used alongside these treatments as a supportive option for selected patients, under medical guidance.

Eligibility depends on individual clinical factors, including imaging studies, circulation assessments, wound status, and overall health. We offer remote consultations in which patients can submit their medical history and relevant exams so our medical team can assess whether MSC-based therapy may be appropriate as a part of an individualized care plan before you even plan your trip.

contact an expert today

Key Research Studies

Therapeutic Angiogenesis Using Bone Marrow Cell Transplantation

The Lancet • 2002

Randomized controlled trial evaluating autologous bone marrow cell transplantation for limb ischemia, demonstrating improved blood flow and clinical outcomes.

View published study

Mesenchymal Stem Cells for Critical Limb Ischemia

Stem Cell Research & Therapy • 2022

Scientific review explaining biological mechanisms and therapeutic potential of mesenchymal stem cells for treating critical limb ischemia.

View published study

Protective Mechanisms of Mesenchymal Stem Cell Therapy

Cellular & Molecular Life Sciences • 2020

Research review detailing cellular and molecular pathways through which MSC-based therapies may promote tissue repair and vascular regeneration.

View published study

Stem Cell Therapy Approaches for Ischemia

International Journal of Molecular Sciences • 2025

Comprehensive scientific review analyzing current innovations, therapeutic strategies, and future directions of stem cell therapy for ischemic conditions.

View published study
info
Location

San José, Costa Rica

Contact Us

info@stemcellstransplantinstitute.com

Call Center

+1 888 785-4170

APPLY TODAY